Treos Bio Company
Treos Bio, Inc. develops precision cancer immunotherapies tailored to patients' genetics.
Estimated Revenue:
$1M to $10M
Funding Status:
Early Stage Venture
Industry:
Peptides and Proteins
Investors Number:
4
Last Funding Date:
2021-03-31
Founded Date:
2013-01-01
Headquarters:
London, England, United Kingdom
Total Funding:
38363455
Last Funding Type:
Convertible Note
Employee Number:
1-10